WallStSmart

Harrow Health Inc (HROW)vsViatris Inc (VTRS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Viatris Inc generates 5619% more annual revenue ($14.30B vs $250.04M). HROW leads profitability with a -2.0% profit margin vs -24.6%. VTRS earns a higher WallStSmart Score of 50/100 (C-).

HROW

Hold

37

out of 100

Grade: F

Growth: 7.3Profit: 4.5Value: 5.0Quality: 5.0

VTRS

Buy

50

out of 100

Grade: C-

Growth: 3.3Profit: 3.5Value: 6.7Quality: 5.5
Piotroski: 4/9Altman Z: 0.80

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HROW2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
45.4%10/10

Revenue surging 45.4% year-over-year

Operating MarginProfitability
20.6%8/10

Strong operational efficiency at 20.6%

VTRS2 strengths · Avg: 10.0/10
PEG RatioValuation
0.1410/10

Growing faster than its price suggests

Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Areas to Watch

HROW4 concerns · Avg: 1.8/10
Price/BookValuation
28.6x2/10

Trading at 28.6x book value

Return on EquityProfitability
-9.6%2/10

ROE of -9.6% — below average capital efficiency

EPS GrowthGrowth
-64.0%2/10

Earnings declined 64.0%

Profit MarginProfitability
-2.0%1/10

Currently unprofitable

VTRS4 concerns · Avg: 1.8/10
Return on EquityProfitability
-21.1%2/10

ROE of -21.1% — below average capital efficiency

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Altman Z-ScoreHealth
0.802/10

Distress zone — elevated risk

Profit MarginProfitability
-24.6%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : HROW

The strongest argument for HROW centers on Revenue Growth, Operating Margin. Revenue growth of 45.4% demonstrates continued momentum.

Bull Case : VTRS

The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.

Bear Case : HROW

The primary concerns for HROW are Price/Book, Return on Equity, EPS Growth.

Bear Case : VTRS

The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.

Key Dynamics to Monitor

HROW profiles as a hypergrowth stock while VTRS is a turnaround play — different risk/reward profiles.

VTRS carries more volatility with a beta of 0.80 — expect wider price swings.

HROW is growing revenue faster at 45.4% — sustainability is the question.

VTRS generates stronger free cash flow (551M), providing more financial flexibility.

Bottom Line

VTRS scores higher overall (50/100 vs 37/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Harrow Health Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Harrow Health, Inc. is an ophthalmology-focused healthcare company. The company is headquartered in San Diego, California.

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?